17.28 -0.39 (-2.21%) | 04-19 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 23.63 | 1-year : | 30.36 |
Resists | First : | 20.23 | Second : | 26 |
Pivot price | 19.15 | |||
Supports | First : | 10.89 | Second : | 9.06 |
MAs | MA(5) : | 18.17 | MA(20) : | 18.87 |
MA(100) : | 15.15 | MA(250) : | 16.09 | |
MACD | MACD : | 0.5 | Signal : | 0.8 |
%K %D | K(14,3) : | 8.4 | D(3) : | 11.7 |
RSI | RSI(14): 46.9 | |||
52-week | High : | 26 | Low : | 9.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELVN ] has closed above bottom band by 20.3%. Bollinger Bands are 29.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 18.56 - 18.67 | 18.67 - 18.75 |
Low: | 15.68 - 15.81 | 15.81 - 15.91 |
Close: | 17.08 - 17.28 | 17.28 - 17.45 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Fri, 19 Apr 2024
Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - MarketBeat
Thu, 18 Apr 2024
Enliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher - MarketBeat
Mon, 15 Apr 2024
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of Stock - MarketBeat
Mon, 15 Apr 2024
Enliven Therapeutics CFO sells over $346k in company stock - Investing.com India
Thu, 11 Apr 2024
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Markets Insider
Thu, 11 Apr 2024
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic ... - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 47 (M) |
Shares Float | 20 (M) |
Held by Insiders | 6.9 (%) |
Held by Institutions | 81 (%) |
Shares Short | 4,230 (K) |
Shares Short P.Month | 4,330 (K) |
EPS | -2.01 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 5.94 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -29 % |
Return on Equity (ttm) | -45 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.76 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -61 (M) |
Levered Free Cash Flow | -33 (M) |
PE Ratio | -8.6 |
PEG Ratio | 0 |
Price to Book value | 2.9 |
Price to Sales | 0 |
Price to Cash Flow | -13.18 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |